Logo
x

Search category

Subscribe Now
Logo

Bristol-Myers' Opdivo and Yervoy Combination Couldn't Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo

Share this

Senior Editor

  • Nov 27, 2018

Biotech

Bristol-Myers' Opdivo and Yervoy Combination Couldn't Meet OS as Maintenance Therapy in esSCLC Patients Post 1L Chemo

Shots:
  • The P-III Checkmate-451 involves assessing Opdivo (nivolumab- 1mg/kg) + Yervoy (ipilimumab-3 mg/kg) vs PBO as a maintenance therapy in patients with extensive-stage small cell lung cancer (SCLC)
  • The study demonstrated unmet 1EPs & 2EPs as OS with no new safety signals observed in patients
  • Opdivo is an PD-1 inhibitor indicated to treat multiple cancer and is currently approved in 65 countries including the US- EU Japan & China
Ref: Bristol-Myers | Image: Irishamerica

Tags

esSCLC Biotech 1L Extensive-Stage SCLC P-III Checkmate-451 Study patients reports results Unmet Maintenance Therapy

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

BMS’ Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine Receives the US FDA’s Approval for the Treatment of Urothelial Carcinoma (UC)

BMS’ Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine Receives the US FDA’s Approval for the Treatment of Urothelial Carcinoma (UC)

  • March 8, 2024
BMS Reports the Acceptance of its sBLA for Opdivo Combination Therapy by the US FDA and EMA for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

BMS Reports the Acceptance of its sBLA for Opdivo Combination Therapy by the US FDA and EMA for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

  • February 8, 2024
BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)

BMS Reports 4-Year Follow-Up Data for Opdivo with Cabometyx in P-III Trial to Treat Advanced Renal Cell Carcinoma (RCC)

  • January 23, 2024
BMS Reports Results from the P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer (mCRC)

BMS Reports Results from the P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer (mCRC)

  • January 22, 2024
BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint

BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint

  • December 8, 2023
BMS’s sBLA for Opdivo-Based Combination Therapy Receives Acceptance for Priority Review by the US FDA for Urothelial Cancer

BMS’s sBLA for Opdivo-Based Combination Therapy Receives Acceptance for Priority Review by the US FDA for Urothelial Cancer

  • December 6, 2023
BMS Receives EMA’s Validation for Opdivo (nivolumab) in Combination with Chemotherapy for the Treatment of Urothelial Carcinoma

BMS Receives EMA’s Validation for Opdivo (nivolumab) in Combination with Chemotherapy for the Treatment of Urothelial Carcinoma

  • October 31, 2023
BMS Reports Three-Year Follow-Up Results from Exploratory Analyses of P-III Trial (CheckMate -816) for Opdivo to Treat Resectable Non-Small Cell Lung Cancer

BMS Reports Three-Year Follow-Up Results from Exploratory Analyses of P-III Trial (CheckMate -816) for Opdivo to Treat Resectable Non-Small Cell Lung Cancer

  • October 18, 2023
Disease of the Month- Mesothelioma

Disease of the Month- Mesothelioma

  • September 14, 2023
BMS Receives the EC Approval for Opdivo (nivolumab) + CT as Neoadjuvant Treatment of Resectable Stage IB to IIIA Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients

BMS Receives the EC Approval for Opdivo (nivolumab) + CT as Neoadjuvant Treatment of Resectable Stage IB to IIIA Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients

  • June 30, 2023

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions
X

Liked our insights or summarized news?

Subscribe to our Daily/Weekly newsletter

Subscribe

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.